Pharming Group N.V. (AMS:PHARM)
Netherlands · Delayed Price · Currency is EUR
1.422
+0.015 (1.07%)
Mar 26, 2026, 5:35 PM CET
Revenue by Segment
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2020 | FY 2018 | FY 2017 | FY 2016 |
|---|
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Jan '20 Jan 1, 2020 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 |
|---|
| 317.90M | 252.24M | 227.13M | 205.62M | - | | | | | |
| 26.03% | 11.05% | 10.46% | - | - | | | | | |
| 58.20M | 44.96M | 18.18M | - | - | | | | | |
| 29.45% | 147.28% | - | - | - | | | | | |
Recombinant Human C1 Esterase Inhibitor Business | - | - | - | - | 198.87M | | | | | |
Recombinant Human C1 Esterase Inhibitor Business Growth | - | - | - | - | -6.27% | | | | | |
| 376.10M | 297.20M | 245.32M | 205.62M | 198.87M | | | | | |
| 26.55% | 21.15% | 19.30% | 3.39% | -6.27% | | | | | |
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2020 | FY 2018 | FY 2017 | FY 2016 |
|---|
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Jan '20 Jan 1, 2020 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 |
|---|
| 361.70M | 287.15M | 239.11M | 200.08M | 193.42M | | | | | |
United States (US) Growth | 25.96% | 20.09% | 19.50% | 3.44% | -4.57% | | | | | |
Europe and The Rest of The World | 14.40M | 10.05M | 6.21M | 5.54M | 5.45M | | | | | |
Europe and The Rest of The World Growth | 43.27% | 61.88% | 12.08% | 1.61% | - | | | | | |
| 376.10M | 297.20M | 245.32M | 205.62M | 198.87M | | | | | |
| 26.55% | 21.15% | 19.30% | 3.39% | -6.27% | | | | | |
Source: S&P Global Market Intelligence.
